rethinkTHC Search
Menu
Study breakdown

Cannabinoid Receptor Changes in HIV-Positive Brains May Explain Cognitive Problems

Cross SectionalPreliminary evidence
The takeaway

Brain tissue analysis found that CB1 and CB2 receptors were differently expressed in people with HIV-associated cognitive disorders compared to those without, with CB1 levels correlating with memory and processing speed deficits.

HIV researchers, neuroimmunologists, medical cannabis researchers

CB1 receptor levels negatively correlated with memory and processing speed in HIV-positive brains

What the researchers found

Immunoblot analysis showed CB1 and CB2 receptors were differentially expressed in frontal cortices of HAND versus neurocognitively unimpaired HIV-positive brains. CB1 expression negatively correlated with memory and processing speed. In HAND brains, CB1 shifted from neuronal processes to cell bodies and showed increased colocalization with astrocytes.

Why it matters

With HIV-associated cognitive disorders persisting despite antiretroviral therapy, identifying endocannabinoid system changes could open new therapeutic targets for the estimated 50% of people with HIV who experience some degree of cognitive impairment.

The numbers in context

CB1 and CB2 differentially expressed in HAND vs NUI brains; CB1 expression negatively correlated with memory and information processing speed; CB1 redistributed from neuronal processes to soma in HAND; increased CB1 colocalization with astroglial marker in HAND.

How the study worked

Cross-sectional biochemical and immunohistochemical analyses of CB1 and CB2 receptor expression in post-mortem brain specimens from people with HIV, comparing those with and without HIV-associated neurocognitive disorders.

What this study cannot tell us

Post-mortem brain analysis cannot establish causation; small sample sizes; cross-sectional design; antiretroviral medication effects not fully controlled; cannot determine if receptor changes preceded or resulted from cognitive decline.

How to read the evidence

Post-mortem brain analysis providing preliminary evidence of endocannabinoid system involvement in HIV-associated cognitive disorders.

When this study was published

Published in 2021.

The bigger picture

The redistribution of cannabinoid receptors in HIV-affected brains suggests that the endocannabinoid system is involved in the cognitive impairment that persists despite viral suppression, potentially explaining why some people with HIV report cognitive benefits from cannabis use.

Questions still open

  • Could cannabinoid-based therapies improve cognitive function in people with HIV? Does cannabis use by people with HIV normalize the receptor redistribution seen in HAND?

Common questions

How does HIV affect cannabinoid receptors in the brain?
In people with HIV-associated cognitive disorders, CB1 receptors were redistributed from their normal locations on neuronal connections to cell bodies and astrocytes, and their expression levels correlated with cognitive deficits.
Could cannabis help HIV-related cognitive problems?
The altered endocannabinoid system in HIV brains suggests it could be a therapeutic target, but this study examined brain tissue, not cannabis treatment. Clinical trials would be needed to determine if cannabinoid therapies could improve cognitive function.

Read the original research

Alterations in Brain Cannabinoid Receptor Levels Are Associated with HIV-Associated Neurocognitive Disorders in the ART Era: Implications for Therapeutic Strategies Targeting the Endocannabinoid System.

Viruses, 13(9)

Citation

Swinton, Mary K; Sundermann, Erin E; Pedersen, Lauren; Nguyen, Jacques D; Grelotti, David J; Taffe, Michael A; Iudicello, Jennifer E; Fields, Jerel Adam. (2021). Alterations in Brain Cannabinoid Receptor Levels Are Associated with HIV-Associated Neurocognitive Disorders in the ART Era: Implications for Therapeutic Strategies Targeting the Endocannabinoid System.. Viruses, 13(9). https://doi.org/10.3390/v13091742

Explore the wider topic